MCID: HMN021
MIFTS: 48

Human T-Cell Leukemia Virus Type 1

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Human T-Cell Leukemia Virus Type 1

MalaCards integrated aliases for Human T-Cell Leukemia Virus Type 1:

Name: Human T-Cell Leukemia Virus Type 1 52
Human T Lymphotropic Virus Type 1 52
Htlv-1 52

Classifications:



Summaries for Human T-Cell Leukemia Virus Type 1

NIH Rare Diseases : 52 Human T-cell leukemia virus , type 1 (HTLV-1) is a retroviral infection that affect the T cells (a type of white blood cell ). Although this virus generally causes no signs or symptoms, some affected people may later develop adult T-cell leukemia (ATL) , HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) or other medical conditions. HTLV-1 is spread by blood transfusions, sexual contact and sharing needles. It can also be spread from mother to child during birth or breast-feeding. There is no cure or treatment for HTLV-1 and it is considered a lifelong condition; however, most (95%) infected people remain asymptomatic (show no symptoms) throughout life.

MalaCards based summary : Human T-Cell Leukemia Virus Type 1, also known as human t lymphotropic virus type 1, is related to adult t-cell leukemia and tropical spastic paraparesis. An important gene associated with Human T-Cell Leukemia Virus Type 1 is CRTC2 (CREB Regulated Transcription Coactivator 2), and among its related pathways/superpathways are ERK Signaling and HIV Life Cycle. The drugs Valproic acid and Zidovudine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and b cells, and related phenotypes are Decreased TP53 mRNA expression and Increased virus production

Wikipedia : 74 Human T-cell lymphotropic virus type 1 or human T-lymphotropic virus type 1 (HTLV-I), also called the... more...

Related Diseases for Human T-Cell Leukemia Virus Type 1

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3

Diseases related to Human T-Cell Leukemia Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 398)
# Related Disease Score Top Affiliating Genes
1 adult t-cell leukemia 32.7 JUND JUN CNTN2
2 tropical spastic paraparesis 31.2 NFKB1 JUN CNTN2
3 t-cell adult acute lymphocytic leukemia 30.9 JUND CREB1 CNTN2
4 human t-cell leukemia virus type 2 29.6 NFKB1 EP300 CREBBP CREB1 CNTN2
5 t-cell leukemia 26.8 XPO1 SRF RPL6 NFKB1 JUND JUN
6 infective dermatitis associated with htlv-1 12.4
7 htlv-1 associated myelopathy/tropical spastic paraparesis 12.1
8 retrovirus-associated myelopathy 11.6
9 intermediate uveitis 11.5
10 pars planitis 11.2
11 myelopathy, htlv-1-associated 10.9
12 spastic paraparesis 10.9
13 human immunodeficiency virus type 1 10.7
14 leukemia 10.7
15 lymphoma 10.5
16 stomatitis 10.5
17 strongyloidiasis 10.5
18 lymphocytic leukemia 10.4
19 uveitis 10.4
20 dermatitis 10.4
21 polymyositis 10.3
22 myopathy 10.3
23 paraplegia 10.3
24 leukemia, chronic lymphocytic 10.3
25 retinoblastoma 10.3
26 immune deficiency disease 10.3
27 osteogenic sarcoma 10.3
28 hepatitis c virus 10.3
29 vaccinia 10.3
30 familial retinoblastoma 10.3
31 severe combined immunodeficiency 10.3
32 mycosis fungoides 10.3
33 myositis 10.3
34 autoimmune disease 10.2
35 bile duct mucoepidermoid carcinoma 10.2 CRTC1 CREB1
36 hypercalcemia, infantile, 1 10.2
37 leukemia, acute lymphoblastic 10.2
38 helix syndrome 10.2
39 diphtheria 10.2
40 arthropathy 10.2
41 b-cell lymphoma 10.2
42 herpes simplex 10.2
43 glioma 10.2
44 glial tumor 10.2
45 acute liver failure 10.2
46 neurogenic bladder 10.2
47 meningitis 10.2
48 retinal vasculitis 10.2
49 clear cell hidradenoma 10.2 CRTC3 CRTC1
50 pleomorphic adenoma carcinoma 10.2 CRTC3 CRTC1

Graphical network of the top 20 diseases related to Human T-Cell Leukemia Virus Type 1:



Diseases related to Human T-Cell Leukemia Virus Type 1

Symptoms & Phenotypes for Human T-Cell Leukemia Virus Type 1

GenomeRNAi Phenotypes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased TP53 mRNA expression GR00389-S-5 9.33 CREB1 JUN NFKB1
2 Increased virus production GR00378-A 9.13 CREB1 EP300 JUND
3 Reduced mammosphere formation GR00396-S 9.1 EP300 JUN JUND RPL6 SRF XPO1

MGI Mouse Phenotypes related to Human T-Cell Leukemia Virus Type 1:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 CDKN1A CNTN2 CREB1 CREBBP CRTC1 GLI2
2 cellular MP:0005384 10.19 CDKN1A CREB1 CREBBP CRTC3 EP300 GLI2
3 homeostasis/metabolism MP:0005376 10.15 CDKN1A CREB1 CREBBP CRTC1 CRTC2 CRTC3
4 growth/size/body region MP:0005378 10.14 CDKN1A CREB1 CREBBP CRTC1 CRTC3 EP300
5 endocrine/exocrine gland MP:0005379 10.13 CDKN1A CREB1 CREBBP CRTC1 EP300 GLI2
6 embryo MP:0005380 10.06 CDKN1A CREB1 CREBBP EP300 GLI2 JUN
7 adipose tissue MP:0005375 10 CDKN1A CREBBP CRTC1 CRTC2 CRTC3 JUND
8 mortality/aging MP:0010768 10 CDKN1A CREB1 CREBBP CRTC3 EP300 GLI2
9 craniofacial MP:0005382 9.95 CDKN1A CREBBP EP300 GLI2 NFKB1 SRF
10 liver/biliary system MP:0005370 9.87 CDKN1A CREBBP CRTC2 CRTC3 JUN JUND
11 muscle MP:0005369 9.81 CDKN1A CREB1 CREBBP CRTC3 EP300 GLI2
12 respiratory system MP:0005388 9.61 CDKN1A CREB1 CREBBP EP300 GLI2 JUN
13 skeleton MP:0005390 9.23 CDKN1A CREB1 CREBBP CRTC3 GLI2 JUN

Drugs & Therapeutics for Human T-Cell Leukemia Virus Type 1

Drugs for Human T-Cell Leukemia Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Zidovudine Approved Phase 4 30516-87-1 35370
3
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
4 Anti-Infective Agents Phase 4
5 Anti-Retroviral Agents Phase 4
6 Antiviral Agents Phase 4
7 Anti-HIV Agents Phase 4
8 Immunologic Factors Phase 4
9 Antimetabolites Phase 4
10 Neurotransmitter Agents Phase 4
11 Anticonvulsants Phase 4
12 interferons Phase 4
13 Central Nervous System Depressants Phase 4
14 Tranquilizing Agents Phase 4
15 GABA Agents Phase 4
16 Psychotropic Drugs Phase 4
17 Antimanic Agents Phase 4
18 Reverse Transcriptase Inhibitors Phase 4
19 Interferon-alpha Phase 4
20 Interferon alpha-2 Phase 4
21
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
22
Lopinavir Approved Phase 2, Phase 3 192725-17-0 92727
23
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
24
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
25
Ivermectin Approved, Investigational, Vet_approved Phase 3 70288-86-7 6474909
26
Mogamulizumab Approved, Investigational Phase 3 1159266-37-1
27 Integrase Inhibitors Phase 2, Phase 3
28 HIV Integrase Inhibitors Phase 2, Phase 3
29 Raltegravir Potassium Phase 2, Phase 3
30
protease inhibitors Phase 2, Phase 3
31 HIV Protease Inhibitors Phase 2, Phase 3
32 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
33 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
34 Platelet Aggregation Inhibitors Phase 3
35 Antioxidants Phase 3
36 Free Radical Scavengers Phase 3
37 Protective Agents Phase 3
38 Vasodilator Agents Phase 3
39 Phosphodiesterase Inhibitors Phase 3
40 Radiation-Protective Agents Phase 3
41 Antiparasitic Agents Phase 3
42
Triamcinolone Approved, Vet_approved Phase 1, Phase 2 124-94-7 31307
43
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
44
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
45
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
46
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
47
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
48
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
49
nivolumab Approved Phase 2 946414-94-4
50
Lenalidomide Approved Phase 2 191732-72-6 216326

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
2 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
3 Evaluation of the Use of Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection in Pregnant Women Presenting With Detectable Viral Load After 32 Weeks of Gestation: a Pilot Study Unknown status NCT01854762 Phase 2, Phase 3 Raltegravir;Lopinavir/Ritonavir
4 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
5 Study Of Valproic Acid To Treat TSP/HAM Patients In Sao Paulo, Brazil Completed NCT00681980 Phase 3 Valproic acid;costicosteroids;valproid acid plus corticosteroids
6 A Comparative Study of Two Regimens of Ivermectin for the Treatment of Strongyloides Stercoralis Infection Recruiting NCT03605758 Phase 3 Ivermectin
7 A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) Active, not recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
8 Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT03355768 Phase 3 Romidepsin;Pralatrexate
9 Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
10 A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia Completed NCT00001941 Phase 1, Phase 2
11 Phase I/II Trial of Dose-Adjusted EPOCH Chemotherapy With Bortezomib Combined With Integrase Inhibitor Therapy for HTLV-1 Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2 Bortezomib;Etoposide;Vincristine;Doxorubicin;Prednisone;Cyclophosphamide;Raltegravir
12 Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
13 Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma Completed NCT02631746 Phase 2
14 A Phase II Study of Lenalidomide in Patients With Relapsed or Refractory HTLV-1 Associated Adult T Cell Leukemia/Lymphoma Completed NCT01274533 Phase 2 Lenalidomide
15 Phase II Trial Of Induction Therapy With EPOCH Chemotherapy And Maintenance Therapy With Combivir/Interferon ALPHA-2a For HTLV-1 Associated T-Cell Non-Hodgkin's Lymphoma Completed NCT00041327 Phase 2 Etoposide;cyclophosphamide;doxorubicin hydrochloride;lamivudine;prednisone;vincristine sulfate;zidovudine
16 Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia Completed NCT00061048 Phase 2
17 A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
18 Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Completed NCT01378871 Phase 2 IMTOX-25
19 Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation Or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT) Completed NCT00711035 Phase 1, Phase 2
20 Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL) Recruiting NCT01712659 Phase 2 Ruxolitinib;ruxolitinib
21 A Phase II Trial of Belinostat as Consolidation Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma Recruiting NCT02737046 Phase 2 Belinostat;Zidovudine;Interferon-Alfa-2b;Pegylated Interferon-Alfa-2b
22 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Active, not recruiting NCT00924170 Phase 1, Phase 2 LMB-2;Fludarabine;Cyclophosphamide
23 Extended Dose - Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory Acute Leukemia And Advanced Myelodysplastic Syndrome Suspended NCT01709396 Phase 2
24 Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load Withdrawn NCT01620736 Phase 2 Raltegravir
25 Immunotherapy of Natural Killer in HTLV-1 Associated Myelopathy Unknown status NCT02961712 Phase 1
26 A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder Unknown status NCT01640002 Phase 1 Propantheline Bromide;Placebo
27 Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease Unknown status NCT02780895 Phase 1 Human Stem Cells
28 Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action Completed NCT00076843 Phase 1 Hu MiK-Beta-1
29 A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma Completed NCT01169298 Phase 1 Lenalidomide
30 A Phase I Study Of Subcutaneous Recombinant Human IL-15 (S.C.rhIL-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL) Recruiting NCT02689453 Phase 1
31 Biomarker Discovery In Children With Autism Plus Familial Autoimmune History Completed NCT01541033
32 Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Completed NCT01651819
33 Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 Completed NCT01754311
34 Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) Completed NCT01867320 Early Phase 1 Raltegravir
35 Sensorimotor Exercises in Virtual Reality Platform and Balance in Individuals With Human T-lymphotropic Virus Completed NCT02877030
36 Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Completed NCT02655471 Early Phase 1 "Raltegravir" and "Zidovudine"
37 Signaling in Tumorigenesis and Immunity Completed NCT01520246
38 MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00034723
39 A Study of Familial and Genetic Aspects of Adult T-Cell Leukemia/Lymphoma, Tropical Spastic Paraparesis and Infective Dermatitis in Jamaica Completed NCT00340821
40 Epidemic History and Iatrogenic Transmission of Blood-borne Viruses Completed NCT02439918
41 Prediagnostic Markers of Adult T-Cell Leukemia/Lymphoma Among Carriers of Human T-Lymphoma Virus Type I: A Collaborative Study Completed NCT00339638
42 Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia Completed NCT02113930
43 Natural History of HTVL-I: A Cross-Sectional Study of a Cohort of Blood Donors in Jamaica Completed NCT00339807
44 Late Effects of Treatment in Survivors of Pediatric Sarcomas Completed NCT00006515
45 Immuno-Virological Evaluation of Human T Cell Lymphotropic Virus Infection and Associated Neurological Diseases Recruiting NCT00001778
46 Collection of Blood, Bone Marrow and Tissue Samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection Recruiting NCT00001582
47 Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer Recruiting NCT00006518
48 Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1 Recruiting NCT03829709
49 Epidemiological and Molecular Aspects of the Interspecies Transmission of Foamy Viruses From Monkeys to Humans: A Model of the Early Stages of Viral Emergence. Recruiting NCT03225794
50 Autologous Ovarian Tissue Transplantation Recruiting NCT03496636

Search NIH Clinical Center for Human T-Cell Leukemia Virus Type 1

Genetic Tests for Human T-Cell Leukemia Virus Type 1

Anatomical Context for Human T-Cell Leukemia Virus Type 1

MalaCards organs/tissues related to Human T-Cell Leukemia Virus Type 1:

40
T Cells, Bone, B Cells, Lung, Breast, Liver, Bone Marrow

Publications for Human T-Cell Leukemia Virus Type 1

Articles related to Human T-Cell Leukemia Virus Type 1:

(show top 50) (show all 2062)
# Title Authors PMID Year
1
Cell death induced by dorsomorphin in adult T-cell leukemia/lymphoma is AMPK-independent. 61
32027454 2020
2
Epidemiology and survival trend of adult T-cell leukemia/lymphoma in the United States. 61
31769871 2020
3
Evaluation of artesunate for the treatment of adult T-cell leukemia/lymphoma. 61
31996318 2020
4
Inefficient Tax-specific T-cell responses in mice after syngeneic transplantation with tax-transgenic mouse-derived adult T-cell leukemia cells. 61
32009059 2020
5
A pilot study to establish human T-cell leukemia virus type 1 (HTLV-1) carrier model using common marmoset (Callithrix jacchus). 61
31930552 2020
6
HTLV-1 bZIP factor: the key viral gene for pathogenesis. 61
31915026 2020
7
Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient. 61
31930455 2020
8
Conservation of a Neutralization Epitope of Human T-cell Leukemia Virus Type 1 (HTLV-1) among Currently Endemic Clinical Isolates in Okinawa, Japan. 61
32012672 2020
9
An RNA Pseudoknot stimulates HTLV-1 pro-pol Programmed -1 Ribosomal Frameshifting. 61
31980578 2020
10
HTLV-1 infection: An emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. 61
31648512 2019
11
TREX1 531C>T Polymorphism is Associated with High Proviral Load Levels in HTLV-1-Infected Persons. 61
31861565 2019
12
HTLV-1 infection of myeloid cells: from transmission to immune alterations. 61
31870397 2019
13
Associations of Viral Seroreactivity with AIDS-Related Non-Hodgkin Lymphoma. 61
31789046 2019
14
HTLV-1 CTCF-binding site is dispensable for in vitro immortalization and persistent infection in vivo. 61
31864373 2019
15
Flower cells of tropical descent: a challenging case of adult T-cell leukemia/lymphoma. 61
31041884 2019
16
Role of HTLV-1 orf-I encoded proteins in viral transmission and persistence. 61
31852543 2019
17
The ESCRT-0 Protein HRS Interacts with the Human T Cell Leukemia Virus Type 2 Antisense Protein APH-2 and Suppresses Viral Replication. 61
31597781 2019
18
Association between human T cell leukemia virus type-1 (HTLV-1) infection and advanced periodontitis in relation to atherosclerosis among elderly Japanese: a cross-sectional study. 61
31883515 2019
19
Population-based prevalence of human T-lymphotropic virus type 1 in sub-Saharan Africa: a systematic review and meta-analysis. 61
31465629 2019
20
Development and evaluation of human T-cell leukemia virus-1 and -2 multiplex quantitative PCR. 61
31429972 2019
21
Separation of the epitopes in a multi-epitope chimera: Helical or flexible linkers? 61
31721685 2019
22
Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. 61
31639014 2019
23
Essential Role of Human T Cell Leukemia Virus Type 1 orf-I in Lethal Proliferation of CD4+ Cells in Humanized Mice. 61
31315992 2019
24
Uncommon association between diabetic ketoacidosis, thyrotoxicosis, cutaneous abscess and acute pericarditis in an immunocompetent patient: a single case report and literature review. 61
31654516 2019
25
HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia. 61
31578308 2019
26
HTLV-positive adult T-cell leukaemia/lymphoma with Epstein-Barr virus and hepatitis B coinfection. 61
31645398 2019
27
Human T-Cell Leukemia Virus Type 1 (HTLV-1) bZIP Factor Upregulates the Expression of ICAM-1 To Facilitate HTLV-1 Infection. 61
31315993 2019
28
Effects of radiation based on whole-body irradiation in HTLV-1-infected mice. 61
31322703 2019
29
The Nature of the HTLV-1 Provirus in Naturally Infected Individuals Analyzed by the Viral DNA-Capture-Seq Approach. 61
31618639 2019
30
Circulating miR-29c, miR-30c, miR-193a-5p and miR-885-5p: Novel potential biomarkers for HTLV-1 infection diagnosis. 61
31242452 2019
31
Prevalence and Molecular Epidemiology of Human T-Lymphotropic Virus Type 1 among Women Attending Antenatal Clinics in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. 61
31407658 2019
32
The time-sequential changes of risk factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study. 61
30246572 2019
33
Clinicopathological analysis of sinonasal malignant lymphoma in an HTLV-1 endemic area in Japan -special focus on primary sinonasal diffuse large B-cell lymphoma. 61
31391402 2019
34
Current mechanistic insights into the role of infection in systemic lupus erythematosus. 61
31226637 2019
35
Conflicting effects of poly(ADP-ribose) polymerase inhibitor on cell-mediated and virion-mediated HTLV-1 infection. 61
31299194 2019
36
Hodgkin-like adult T-cell leukemia/lymphoma that developed during the follow-up of HTLV-1 associated myelopathy/tropical spastic paraparesis. 61
31391405 2019
37
Silencers of HTLV-1 and HTLV-2: the pX-encoded latency-maintenance factors. 61
31492165 2019
38
Complete sequence of human T cell leukemia virus type 1 in ATLL patients from Northeast Iran, Mashhad revealed a prematurely terminated protease and an elongated pX open reading frame III. 61
31102740 2019
39
The human T-cell leukemia virus type-1 tax oncoprotein dissociates NF-κB p65RelA-Stathmin complexes and causes catastrophic mitotic spindle damage and genomic instability. 61
31299491 2019
40
[Human Oncogenic Viruses: Old Facts and New Hypotheses]. 61
31661485 2019
41
Current approaches for detection of human T-lymphotropic virus Type 1: A systematic review. 61
30633358 2019
42
Comparative virology of HTLV-1 and HTLV-2. 61
31391116 2019
43
Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 Activities In Vitro and In Vivo. 61
31167921 2019
44
Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL. 61
31438973 2019
45
Initial human T-cell leukemia virus type 1 infection of the salivary gland epithelial cells requires a biofilm-like structure. 61
31233774 2019
46
Novel Interactions between the Human T-Cell Leukemia Virus Type 1 Antisense Protein HBZ and the SWI/SNF Chromatin Remodeling Family: Implications for Viral Life Cycle. 61
31142665 2019
47
High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments. 61
31292228 2019
48
Adult T-Cell Leukemia After Deceased Donor Liver Transplantation for Acute Liver Failure: A Case Report. 61
31303413 2019
49
Cutaneous manifestations of adult T-cell leukemia/lymphoma. 61
31387753 2019
50
The prevalence of human T-lymphotropic virus type 1 & 2 (HTLV-1/2) in South African blood donors. 61
30950074 2019

Variations for Human T-Cell Leukemia Virus Type 1

Expression for Human T-Cell Leukemia Virus Type 1

Search GEO for disease gene expression data for Human T-Cell Leukemia Virus Type 1.

Pathways for Human T-Cell Leukemia Virus Type 1

Pathways related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 SRF NFKB1 JUND JUN EP300 CREBBP
2
Show member pathways
13.74 XPO1 RPL6 NFKB1 JUN EP300 CREBBP
3
Show member pathways
13.73 XPO1 SRF NFKB1 JUN EP300 CREBBP
4
Show member pathways
13.26 SRF NFKB1 JUN EP300 CREBBP CREB1
5
Show member pathways
13.15 NFKB1 JUND JUN EP300 CREBBP CREB1
6
Show member pathways
13.05 NFKB1 JUND JUN GLI2 EP300 CREBBP
7
Show member pathways
13.03 NFKB1 EP300 CRTC2 CREBBP CREB1 CDKN1A
8
Show member pathways
13.01 NFKB1 JUN EP300 CREBBP CDKN1A ATF1
9
Show member pathways
12.98 NFKB1 JUN EP300 CREBBP CREB1 CDKN1A
10
Show member pathways
12.95 SRF NFKB1 JUND JUN ATF1
11
Show member pathways
12.94 EP300 CREBBP CREB1 CDKN1A ATF1
12
Show member pathways
12.92 SRF NFKB1 JUN EP300 CREBBP
13
Show member pathways
12.91 SRF NFKB1 JUN EP300 CREBBP CREB1
14
Show member pathways
12.91 NFKB1 JUN EP300 CREBBP CREB1 CDKN1A
15
Show member pathways
12.89 CRTC3 CRTC2 CRTC1 CREBBP CREB1
16 12.88 NFKB1 JUN GLI2 EP300 CREBBP CDKN1A
17
Show member pathways
12.85 XPO1 NFKB1 JUN EP300 CREBBP CDKN1A
18
Show member pathways
12.81 NFKB1 JUND JUN CREB1 CDKN1A ATF1
19
Show member pathways
12.73 NFKB1 JUN EP300 CREBBP CREB1
20
Show member pathways
12.73 NFKB1 JUN EP300 CREBBP CREB1
21
Show member pathways
12.68 NFKB1 JUN CREBBP CREB1
22
Show member pathways
12.67 NFKB1 JUN EP300 CREBBP CDKN1A
23
Show member pathways
12.59 NFKB1 EP300 CREBBP CDKN1A
24
Show member pathways
12.59 JUN GLI2 EP300 CREBBP CDKN1A
25 12.57 NFKB1 EP300 CREBBP CDKN1A
26
Show member pathways
12.57 NFKB1 JUN CREB1 ATF1
27
Show member pathways
12.53 NFKB1 JUN EP300 CREBBP CREB1
28
Show member pathways
12.45 SRF NFKB1 JUN CREB1
29
Show member pathways
12.45 NFKB1 JUND JUN CREB1
30
Show member pathways
12.44 NFKB1 EP300 CREB1 CDKN1A
31 12.37 NFKB1 JUN EP300 CREBBP CREB1
33 12.3 NFKB1 EP300 CREBBP CREB1
34
Show member pathways
12.29 XPO1 NFKB1 JUN CDKN1A
35
Show member pathways
12.27 NFKB1 JUND JUN CREB1
36
Show member pathways
12.27 NFKB1 JUND JUN EP300 CREB1 ATF1
37
Show member pathways
12.25 SRF EP300 CREBBP CREB1
38
Show member pathways
12.25 NFKB1 JUND JUN EP300 CREBBP
39 12.24 JUND JUN CREB1 ATF1
40 12.22 SRF NFKB1 JUN EP300 CREBBP CREB1
41 12.21 NFKB1 JUN EP300 CREBBP CREB1
42 12.17 NFKB1 JUN CRTC1 CREB1
43 12.14 NFKB1 JUN EP300 CREB1 ATF1
44
Show member pathways
12.13 SRF NFKB1 JUN CREBBP CREB1
45
Show member pathways
12.13 EP300 CRTC3 CRTC2 CRTC1 CREBBP CREB1
46 12.12 JUN EP300 CREBBP CDKN1A
47 12.11 NFKB1 JUND JUN CREB1
48
Show member pathways
12.1 EP300 CREBBP CDKN1A
49
Show member pathways
12.08 NFKB1 JUND JUN ATF1
50
Show member pathways
12.07 CRTC3 CRTC2 CRTC1 CREBBP CREB1

GO Terms for Human T-Cell Leukemia Virus Type 1

Cellular components related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.83 XPO1 SRF RPL6 NFKB1 JUND JUN
2 nuclear chromatin GO:0000790 9.8 SRF NFKB1 JUND JUN CREBBP CREB1
3 transcription factor complex GO:0005667 9.55 JUND JUN EP300 CREB1 ATF1
4 nucleoplasm GO:0005654 9.47 XPO1 SRF NFKB1 JUND JUN GLI2
5 transcription factor AP-1 complex GO:0035976 9.32 JUND JUN

Biological processes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10 XPO1 NFKB1 JUND JUN GLI2 EP300
2 regulation of transcription, DNA-templated GO:0006355 9.97 SRF RPL6 NFKB1 JUND JUN EP300
3 response to drug GO:0042493 9.91 XPO1 JUND JUN CREB1 CDKN1A
4 heart development GO:0007507 9.89 SRF GLI2 EP300 CDKN1A
5 transcription by RNA polymerase II GO:0006366 9.88 SRF NFKB1 JUND JUN CREB1
6 response to hypoxia GO:0001666 9.87 SRF EP300 CREBBP CREB1
7 regulation of cell cycle GO:0051726 9.86 JUND JUN EP300 CDKN1A
8 rhythmic process GO:0048511 9.85 EP300 CRTC1 CREBBP CREB1
9 response to organic cyclic compound GO:0014070 9.83 JUND JUN CDKN1A ATF1
10 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.8 NFKB1 EP300 CREBBP
11 positive regulation of transcription, DNA-templated GO:0045893 9.8 SRF NFKB1 JUN GLI2 EP300 CREBBP
12 protein homotetramerization GO:0051289 9.77 CRTC3 CRTC2 CRTC1
13 positive regulation of type I interferon production GO:0032481 9.76 NFKB1 EP300 CREBBP
14 positive regulation of cell differentiation GO:0045597 9.75 SRF JUND JUN
15 response to organic substance GO:0010033 9.73 JUND JUN CREB1 CDKN1A
16 circadian rhythm GO:0007623 9.71 JUND JUN EP300 CREB1
17 positive regulation of DNA replication GO:0045740 9.67 JUN GLI2 ATF1
18 positive regulation of long-term synaptic potentiation GO:1900273 9.65 CRTC1 CREB1
19 platelet formation GO:0030220 9.65 SRF EP300
20 osteoblast development GO:0002076 9.64 JUND GLI2
21 positive regulation of transcription of Notch receptor target GO:0007221 9.64 EP300 CREBBP
22 positive regulation by host of viral transcription GO:0043923 9.63 JUN EP300
23 megakaryocyte development GO:0035855 9.63 SRF EP300
24 response to muscle stretch GO:0035994 9.62 NFKB1 JUN
25 protein acetylation GO:0006473 9.61 EP300 CREBBP
26 eyelid development in camera-type eye GO:0061029 9.61 SRF JUN
27 N-terminal peptidyl-lysine acetylation GO:0018076 9.54 EP300 CREBBP
28 positive regulation of CREB transcription factor activity GO:0032793 9.54 CRTC3 CRTC2 CRTC1
29 viral process GO:0016032 9.5 XPO1 EP300 CRTC3 CRTC2 CRTC1 CREBBP
30 response to cytokine GO:0034097 9.46 SRF NFKB1 JUND JUN
31 positive regulation of transcription by RNA polymerase II GO:0045944 9.4 SRF NFKB1 JUND JUN GLI2 EP300

Molecular functions related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.39 XPO1 SRF NFKB1 JUND JUN GLI2
2 DNA binding GO:0003677 10.15 SRF RPL6 NFKB1 JUND JUN GLI2
3 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 10.02 SRF NFKB1 JUND JUN GLI2 CREB1
4 DNA-binding transcription factor activity GO:0003700 10 SRF NFKB1 JUND JUN GLI2 CREB1
5 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.91 SRF JUND JUN GLI2 EP300 CREB1
6 sequence-specific DNA binding GO:0043565 9.91 SRF NFKB1 JUND JUN GLI2 CREB1
7 transcription coactivator activity GO:0003713 9.84 JUND JUN EP300 CREBBP
8 transcription regulatory region DNA binding GO:0044212 9.8 NFKB1 JUND JUN GLI2 CREB1
9 double-stranded DNA binding GO:0003690 9.74 JUND JUN CREB1
10 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 9.73 NFKB1 JUN CREB1
11 transcription coregulator activity GO:0003712 9.7 EP300 CREBBP CREB1
12 chromatin binding GO:0003682 9.7 SRF NFKB1 JUN GLI2 EP300 CRTC2
13 RNA polymerase II activating transcription factor binding GO:0001102 9.62 JUN EP300 CREBBP CREB1
14 acetyltransferase activity GO:0016407 9.58 EP300 CREBBP
15 cAMP response element binding GO:0035497 9.55 JUN CREB1
16 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.5 SRF NFKB1 JUND JUN GLI2 CREB1
17 cAMP response element binding protein binding GO:0008140 9.43 CRTC3 CRTC2 CRTC1
18 transcription factor binding GO:0008134 9.23 SRF NFKB1 JUND JUN GLI2 EP300

Sources for Human T-Cell Leukemia Virus Type 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....